The Provincial Drug Administration held a seminar on the administrative licensing of pharmaceuticals, medical devices and cosmetics in the province
On November 17, the Provincial Drug Administration held a 2021 symposium on the administrative licensing of pharmaceuticals, medical devices and cosmetics in the province in Zhongshan. The meeting summarized the administrative licensing work of the province since 2021, and deployed the next key work. Su Shengfeng, a member of the Party Leadership Group of the Provincial Drug Administration, attended the symposium and delivered a speech.
The meeting pointed out that since 2021, the province’s drug regulatory agencies have thoroughly implemented the decisions and deployments of the National Food and Drug Administration and the provincial party committee and government, centered on the overall requirements of the province’s comprehensive drug regulatory reform and the focus of administrative licensing work, dare to take up the heavy burdens, and resolutely shoulder Ensure the responsibility and mission of the supply of pharmaceutical equipment for epidemic prevention and control, fully serve the overall situation of epidemic prevention and control, continue to deepen the reform of the medical equipment review and approval system and the reform of “delegation of control and service”, implement the key tasks of pharmaceutical equipment supervision and innovation in the Guangdong-Hong Kong-Macao Greater Bay Area, and vigorously promote the biomedical industry High-quality development and remarkable work results have been achieved.
The meeting made arrangements for the next step of the work. First, we must continue to make every effort to ensure the overall situation of epidemic prevention and control services, deeply understand the significance of doing a good job in the registration and approval of epidemic prevention and control drugs, and do not relax the quality of emergency review and approval. The second is to continue to deepen the reform of “delegating control and service”, improve drug regulatory capabilities, strengthen industry service awareness, further improve drug safety governance, and actively participate in promoting the construction of a drug safety governance demonstration zone and a high-quality development demonstration zone for the pharmaceutical industry in Guangdong Province. The third is to optimize the Greater Bay Area’s regulatory innovation policies and measures, seize the major opportunities of the Greater Bay Area’s construction, actively integrate into the Greater Bay Area’s pharmaceutical and device regulatory innovation and development work, and strengthen the in-depth docking and cooperation with Hong Kong and Macau in the field of biomedical industry supervision. The fourth is to comprehensively promote the high-quality development of the pharmaceutical industry, implement the development of strategic pillar industry clusters in biomedicine and health, increase service measures, further improve various systems and mechanisms, and promote the high-quality development of the biopharmaceutical industry to continuously achieve new results.
The listing market supervision bureau and the three free trade zone market supervision departments conducted work exchanges at the meeting. A total of 100 people from the relevant departments and offices of the Provincial Drug Administration, directly affiliated units, and local-level comrades in charge of the listing market supervision bureau and related staff attended the meeting. (Contribution/Pictures from the Administrative Licensing Office of the Provincial Bureau)